Congress Eyes Vaccine Pricing With Spotlight On Pfizer As COVID Boosters Look More Likely
Senate hearing offers early signals that US lawmakers will be closely watching how COVID-19 vaccine pricing evolves. Biden team pledges to try to make contracting more transparent.
You may also be interested in...
US Gov't Plans To Control COVID Vaccine Distribution At Least Through 2022; Already Authorized Products Have Booster Advantage
Due to need to plan for potential vaccine boosters now, administration is focusing on contracting with the companies whose shots are already being given in the US, David Kessler tells the Senate health committee. Data on whether it is ok to ‘mix and match’ vaccine types with boosters should be available in a few months.
America still has a long way to go to meaningfully contribute to ending the global pandemic, but loaning AstraZeneca’s vaccine to Canada and Mexico helps counter the narrative that only China and Russia are helping the rest of the world.
A Senate hearing on the US COVID-19 response recalled Kessler’s tenure as FDA commissioner a quarter century ago – and included some reminders that things have changed.